EC Number   |
Application |
Reference |
|---|
   3.4.17.23 | medicine |
ACE2 offers a new target for the treatment of hypertension and other cardiovascular diseases |
691838 |
| 3.4.17.23 | medicine |
ACE2 protects against acute lung injury in several animal models of acute respiratory distress syndrome. Increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases |
668354 |
| 3.4.17.23 | medicine |
ACE2 protects murine lungs from acute respiratory distress syndrome |
679703 |
| 3.4.17.23 | analysis |
ACE2-based biosensor designed to detect both SARS-CoV-2 S1 mutations and neutralizing antibodies. In binding mode, the biosensor works by detecting binding of the spike protein to an immobilized ACE2 receptor and is able to detect S1 proteins of the alpha (500 pg/ml) and beta variants (10 ng/ml), as well as wild-type S1 (10 ng/ml), of SARSCoV-2 and it distinguishes wild-type SARS-CoV-2 S1 from the S1 alpha and beta variants via color differences. A modification to the protocol enables the ACE2-based biosensor to operate in blocking mode to detect neutralizing antibodies in serum samples from COVID-19 patients |
764335 |
| 3.4.17.23 | medicine |
ACE2-overexpressing A549 cell-derived microparticles are a potential therapeutic agent against SARS-CoV-2 infection. Intranasally administered microparticles dexterously navigate the anatomical and biological features of the lungs to enter the alveoli and are taken up by alveolar macrophages. Then, ACE2-overexpressing A549 cell-derived microparticles increase the endosomal pH but decrease the lysosomal pH in alveolar macrophages, thus escorting bound SARS-CoV-2 from phago-endosomes to lysosomes for degradation. In addition, ACE2-overexpressing A549 cell-derived microparticles also inhibit the proinflammatory phenotype of alveolar macrophages, leading to increased treatment efficacy in a SARS-CoV-2-infected mouse model without side effects |
764444 |
| 3.4.17.23 | medicine |
administration of ACE2 activators may be a valid strategy for antihypertensive therapy |
692586 |
| 3.4.17.23 | medicine |
among 226000 SARSCoV-2 sequences, 1573 missense mutations are found in the spike gene, and 226 of them were within the receptor-binding domain region that directly interacts with human ACE2. Modeling shows that most of the 74 missense mutations in the receptor-binding domain region of the interaction interface have little impact on spike binding to ACE2, whereas several within the spike receptor-binding domain increase the binding affinity toward human ACE2 thus making the virus likely more contagious |
764531 |
| 3.4.17.23 | analysis |
analysis of the interaction between ACE2 and SARS-CoV-2 spike protein using a surface plasmon resonance-based assay that reduces the heterogeneity introduced from multivalent binding interactions to enable the determination of the kinetic rate constants for multivalent binding interactions. Controlling the sensor surface heterogeneity enables the deconvolution of the avidity-induced affinity enhancement for the SARS-CoV-2 spike protein and ACE2 interaction |
763883 |
| 3.4.17.23 | medicine |
analysis of variations in SARS-CoV-2 spike protein and hACE2 receptor protein and their interaction in the infection scale. Interactions of hACE2 variants with SARS-CoV-2 variants are very strong for G726R-G476S, R768W-V367F, Y252N-V483A, Y252N-V367F, G726R-V367F, N720D-V367F and N720DF486L, and weak for P263S-S383C, RBD-H378R, G726R-A348T |
765112 |
| 3.4.17.23 | medicine |
angiotensin converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, but only ACE2 of certain species can be utilized by SARS-CoV-2. SARS-CoV-2 tends to utilize ACE2 of various mammals, except murines, and some birds, such as pigeon. This prediction may help to screen the intermediate hosts of SARS-CoV-2. SARS-CoV-2 has a high genetic relationship with a bat coronavirus (BatCoV RaTG13) with a 96% genomic nucleotide sequence identity. The close phylogenetic relationship to Bat RaTG13 provides evidence for a bat origin of SARS-CoV-2. Direct transmission of the virus from bats to humans is unlikely due to the lack of direct contact between bats and humans (in Wuhan, China). There are probably intermediate hosts transmitting SARS-CoV-2 to humans. Combined phylogenetic analysis and critical site marking is used to predict the utilizing capability of ACE2 from different animal species by SARS-CoV-2. It is confirmed that pangolin (Manis javanica), cat (Felis catus), cow (Bos taurus), buffalo (Bubalus bubalis), goat (Capra hircus), sheep (Ovis aries) and pigeon (Columba livia) ACE2 might be utilized by SARS-CoV-2, indicating potential interspecies transmission of the virus from bats to these animals and among these animals |
754646 |
